Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms
Therapeutic Advances in Psychopharmacology · 2025-10 · 15
DOI: 10.1177/20451253251371504 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 31.10.2025. Verfasst von Mark Abie Horowitz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Development, North East London Foundation Trust, Goodmayes Hospital, 157 Barley Ln, Goodmayes, Ilford IG3 8XJ, UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Formal guidelines recommend that opioids should be stopped when risks outweigh benefits. These guidelines generally recommend gradual dose tapering at a rate tolerable to the patient. However, there is considerable variation regarding the pattern of dose tapering recommended, with some suggesting linear tapers (with a fixed reduction of dose at each step), while others recommend increasingly small dose reductions as the total dose gets lower. No biological rationale has been put forward for these recommendations. We examined the pharmacodynamic properties of opioids to derive pharmacologically rational principles for tapering. As dictated by the law of mass action, the relationship between dose of opioid and effect on its principal target, the mu-opioid receptor, is hyperbolic, with diminishing incremental effects for increasing doses. This suggests that in order to mitigate withdrawal symptoms, opioid doses should be tapered according to a corresponding hyperbolic pattern, with dose reductions becoming increasingly small as total dose reduces. This can be approximated by proportional decreases (e.g. 1%–10% reduction of the most recent dose every 1–2 weeks). Dose reductions should be titrated to withdrawal symptoms throughout the process, and final doses before complete cessation will need to be very small (such as 0.1 mg of buprenorphine or 1 mg of methadone, or less). The duration required for this strategy of tolerable tapering after long-term use may require many months or years for some patients. The theoretical proposals in this paper offer a pharmacologically rational strategy that should prompt review of clinical practice and guidelines. Gradual, hyperbolic tapering should be evaluated in randomised controlled trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Research and Development, North East London Foundation Trust, Goodmayes Hospital, 157 Barley Ln, Goodmayes, Ilford IG3 8XJ, UK.
- Psychotropic Deprescribing Council, San Francisco, CA, USA.
- King's College London, National Addiction Centre, London, UK.
- South London and Maudsley NHS Foundation Trust, London, UK.
- Institute of Pharmaceutical Science, King's College London, London, UK.
ORCID-Profile: Mark Abie Horowitz, Adele Framer, John Strang, David Taylor
Zitieren
APA
Abie Horowitz, M., Framer, A., Strang, J., & Taylor, D. (2025). Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms. Therapeutic Advances in Psychopharmacology, 15. https://doi.org/10.1177/20451253251371504
Vancouver
Abie Horowitz M, Framer A, Strang J, Taylor D. Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms. Therapeutic Advances in Psychopharmacology. 2025;15. doi:10.1177/20451253251371504
BibTeX
@article{AbieHorowitz2025,
author = {Abie Horowitz, Mark and Framer, Adele and Strang, John and Taylor, David},
title = {Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms},
journal = {Therapeutic Advances in Psychopharmacology},
year = {2025},
volume = {15},
doi = {10.1177/20451253251371504}
}
EUVIMED